Ascendis Pharma (ASND) reported a Q3 loss late Thursday of 1.72 euros ($1.81) per diluted share, narrower than a loss of 2.88 euros loss a year earlier.
Analysts polled by Capital IQ expected a loss of 1.46 euros.
Revenue for the quarter that ended Sept. 30 was 57.8 million euros, up from 48 million euros a year earlier.
Analysts surveyed by Capital IQ expected 70.3 million euros.
Shares of the company were about 8% lower in recent after-hours activity.
Price: 114.50, Change: -9.78, Percent Change: -7.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.